Yazar "Alarcin, Emine" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Biosensor integrated brain-on-a-chip platforms: Progress and prospects in clinical translation
    (Elsevier Advanced Technology, 2023) Cecen, Berivan; Saygili, Ecem; Zare, Iman; Nejati, Omid; Khorsandi, Danial; Zarepour, Atefeh; Alarcin, Emine
    Because of the brain's complexity, developing effective treatments for neurological disorders is a formidable challenge. Research efforts to this end are advancing as in vitro systems have reached the point that they can imitate critical components of the brain's structure and function. Brain-on-a-chip (BoC) was first used for microfluidics-based systems with small synthetic tissues but has expanded recently to include in vitro simulation of the central nervous system (CNS). Defining the system's qualifying parameters may improve the BoC for the next generation of in vitro platforms. These parameters show how well a given platform solves the problems unique to in vitro CNS modeling (like recreating the brain's microenvironment and including essential parts like the blood-brain barrier (BBB)) and how much more value it offers than traditional cell culture systems. This review provides an overview of the practical concerns of creating and deploying BoC systems and elaborates on how these technologies might be used. Not only how advanced biosensing technologies could be integrated with BoC system but also how novel approaches will automate assays and improve point-of-care (PoC) diagnostics and accurate quantitative analyses are discussed. Key challenges providing opportunities for clinical translation of BoC in neurodegenerative disorders are also addressed.
  • Küçük Resim
    Öğe
    Design of an amphiphilic hyperbranched core/shell-type polymeric nanocarrier platform for drug delivery
    (TUBITAK, 2022) Bal Öztürk, Ayça; Oğuz, Nesrin; Tekarslan Şahin, Hande; Emik, Serkan; Alarcin, Emine
    An amphiphilic core/shell-type polymer-based drug carrier system (HPAE- PCL-b-MPEG), composed of hyperbranched poly(aminoester)-based polymer (HPAE) as the core building block and poly(ethylene glycol)-bpoly(?-caprolactone) diblock polymers (MPEG-b-PCL) as the shell building block, was designed. The synthesized polymers were characterized with FTIR, 1 H NMR, 13 C NMR, and GPC analysis. Monodisperse HPAE-PCL-b-MPEG nanoparticles with dimensions of <200 nm and polydispersity index of <0.5 were prepared by nanoprecipitation method and characterized with SEM, particle size, and zeta potential analysis. 5-Fluorouracil was encapsulated within HPAE-PCL-b-MPEG nanoparticles. In vitro drug release profiles and cytotoxicity of blank and 5-fluorouracil-loaded nanoparticles were examined against the human colon cancer HCT116 cell line. All results suggest that HPAE-PCL-b-MPEG nanoparticles offer an alternative and effective drug nanocarrier system for drug delivery applications. © TÜBİTAK.
  • Küçük Resim Yok
    Öğe
    Hyperbranched polymer-based nanoparticle drug delivery platform for the nucleus-targeting in cancer therapy
    (Elsevier, 2023) Bal-Ozturk, Ayca; Tietilu, Sherif Domingo; Yuecel, Oguz; Erol, Tugba; Akguner, Zeynep Puren; Darici, Hakan; Alarcin, Emine
    Hyperbranched polymers (HPB) are drawing attention as one of the drug delivery platforms that can encapsulate drugs owing to the internal voids in their three-dimensional construct. It is feasible to develop HBP-based nano -sized drug delivery platforms and improve the efficacy of cancer treatment due to its potential properties. In particular, the contribution of targeted drug delivery systems that can target malignant tissues in the treatment processes is undeniable. For this purpose, modifying an HBP-based nanoparticle delivery system with a targeting molecule is vital. In this study, we synthesized folic acid-modified HBP-based nanoparticles and their physical (DLS, zeta potential) and chemical (FTIR, NMR) characterizations were performed, and finally 5-Fluorouracil (5-FU) was loaded as a model active agent. The release properties (UV-VIS) and release kinetic models of 5-FU-loaded folic acid-modified nanoparticles were investigated in different pHs. In vitro cellular activities (MTT, cellular uptake) and targeting properties to the folate receptor (FR) were determined by flow cytometry on HeLa (FR, +) and L929 (FR,-) cells. According to all the results, folic acid-modified HBP-based nanoparticles were efficiently transported to the cell nucleus in the targeted FR + cells, and internalization of nanoparticles in HeLa cells is similar to 2.5 times higher than L929 cells. All results suggest that folic acid modification to the nanoparticles is critical in folate receptor-positive cancer treatment.